Healthcare
•3762 stocks
•
Total Market Cap: Loading...
Nov 04, 2025
|
Prenetics’ IM8 Brand Generates Record $9 Million Monthly Revenue in October, Surpassing $108 Million ARR
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3762)
| Company | Market Cap | Price |
|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
Core PEDD drug-delivery platform technology powering TriNav systems.
|
$178.22M |
$4.73
+0.42%
|
|
ACHV
Achieve Life Sciences, Inc.
Cytisinicline is an oral small-molecule therapeutic candidate for smoking cessation, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$177.24M |
$4.83
-5.38%
|
|
KRMD
KORU Medical Systems, Inc.
KRMD's core business is medical devices focused on patient-centric subcutaneous infusion systems (Freedom) and related components.
|
$177.18M |
$3.84
|
|
CCCC
C4 Therapeutics, Inc.
Lead assets (e.g., cemsidomide) are orally bioavailable small-molecule degraders, fitting the 'Oral Small Molecule Therapeutics' category.
|
$176.10M |
$2.29
-7.86%
|
|
IMDX
Insight Molecular Diagnostics Inc.
IMDX directly provides Laboratory Testing & Advisory Services via its GraftAssure family (LDTs/kits) for transplant rejection monitoring.
|
$175.03M |
$6.11
-0.25%
|
|
NYXH
Nyxoah S.A.
Genio is a neuromodulation implant system (implantable medical device) for obstructive sleep apnea.
|
$174.70M |
$5.03
-0.98%
|
|
SKIN
The Beauty Health Company
High-margin disposable consumables (tips, solutions, serums) sold for Hydrafacial devices create a recurring revenue stream, matching Medical Device Consumables.
|
$172.61M |
$1.34
-1.82%
|
|
MXCT
MaxCyte, Inc.
ExPERT medical device platform for cell engineering and its related consumables constitute MaxCyte's core product offerings in healthcare hardware.
|
$171.17M |
$1.60
-0.31%
|
|
RCMT
RCM Technologies, Inc.
RCMT's offerings align with Healthcare Services & Facilities through its healthcare staffing/model and service delivery to care institutions.
|
$170.94M |
$23.31
+0.78%
|
|
PRE
Prenetics Global Limited
Insighta's FRAGMA liquid biopsy enables multi-cancer early detection.
|
$165.86M |
$12.92
-4.79%
|
|
CYDY
CytoDyn Inc.
Leronlimab is a monoclonal antibody therapeutic, aligning CytoDyn with Monoclonal Antibody Therapeutics.
|
$160.94M |
$0.24
|
|
BHST
BioHarvest Sciences Inc. Common Stock
BioHarvest operates a CDMO division providing contract development and manufacturing services for plant-based compounds.
|
$160.28M |
$8.96
-3.14%
|
|
RELL
Richardson Electronics, Ltd.
Medical devices and equipment manufacturing including CT X-ray tubes and related products remain part of the portfolio.
|
$157.24M |
$10.68
-1.61%
|
|
EHTH
eHealth, Inc.
eHealth's core business is to facilitate enrollment in health insurance products (Medicare and other plans).
|
$157.09M |
$4.98
-3.86%
|
|
AVR
Anteris Technologies Global Corp.
Company directly develops and sells medical devices for the cardiovascular field, specifically the DurAVR transcatheter heart valve and related biomaterial technologies.
|
$156.87M |
$4.38
+0.80%
|
|
THTX
Theratechnologies Inc.
EGRIFTA WR and TH1902 are peptide-based therapeutics, representing Theratechnologies' core peptide therapeutics business.
|
$155.87M |
$3.39
|
|
CGEN
Compugen Ltd.
Company focus and programs are centered in oncology/immuno-oncology, qualifying under Biotech - Oncology.
|
$154.90M |
$1.64
-5.49%
|
|
SAVA
Cassava Sciences, Inc.
Direct product category: simufilam is developed as an oral small-molecule therapeutic.
|
$154.10M |
$3.04
-4.55%
|
|
IPHA
Innate Pharma S.A.
Innate Pharma focuses on oncology therapies, including antibody-based approaches, making Biotech - Oncology a core business area.
|
$153.84M |
$1.87
-1.58%
|
|
CRDF
Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company focused on oncology therapeutics, with its lead asset targeting cancer (onvansertib).
|
$153.67M |
$2.21
-4.11%
|
|
CABA
Cabaletta Bio, Inc.
Core product category: CAR-T cell therapy platform (CARTA) and rese-cel directly produced by Cabaletta.
|
$152.74M |
$2.69
-10.80%
|
|
OBIO
Orchestra BioMed Holdings, Inc.
AVIM therapy is an implantable cardiac stimulation-based treatment for hypertension, aligning with Cardiology Devices.
|
$151.33M |
$3.71
-5.95%
|
|
AVHHL
AVITA Medical, Inc.
AVITA Medical’s core offerings are wound care devices and dermal matrices (RECELL system, RECELL GO, PermeaDerm, Cohealyx) used in wound management, fitting the Wound Care Devices category.
|
$150.63M |
$1.11
|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
Corbus's pipeline is focused on oncology assets (CRB-701 and CRB-601) representing biotech oncology products.
|
$150.51M |
$11.48
-6.67%
|
|
NVCT
Nuvectis Pharma, Inc.
Nuvectis' lead asset NXP900 is a cancer-targeting therapy (SRC/YES1 kinase inhibitor), placing the company in Biotech - Oncology.
|
$150.32M |
$5.91
-7.08%
|
|
PEPG
PepGen Inc.
PepGen's PGN-EDODM1 is an oligonucleotide therapeutic targeting DM1, aligning directly with Oligonucleotide Therapeutics.
|
$148.23M |
$4.54
+0.11%
|
|
ELTX
Elicio Therapeutics, Inc.
Lead product candidate is a cancer vaccine/immunotherapy, aligning with Vaccines.
|
$147.97M |
$9.22
-0.27%
|
|
HIT
Health In Tech, Inc.
HIT operates in health insurance by enabling quotes, plans, and related services through its platform.
|
$147.62M |
$2.92
+7.96%
|
|
LNSR
LENSAR, Inc.
Direct ophthalmic device product (Ophthalmology Devices) produced by LENSAR via the ALLY robotic cataract laser system.
|
$147.40M |
$12.18
-2.56%
|
|
APLT
Applied Therapeutics, Inc.
Applied Therapeutics is a biotech focused on rare diseases, with lead programs in rare metabolic/neurologic conditions (e.g., govorestat for CMT-SORD) and out-licensing efforts in rare disease assets.
|
$147.24M |
$1.01
-2.40%
|
|
PROF
Profound Medical Corp.
Profound's flagship TULSA-PRO is a surgical device used for MR-guided prostate tissue ablation.
|
$146.98M |
$5.88
-1.26%
|
Showing page 23 of 38 (3762 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
